Gender differences in antiplatelet therapy of ischaemic heart disease


  • I. A. Zupanets National University of Pharmacy, Ukraine
  • O. E. Zaprovalna State Institute “National Institute of Therapy named after L.T. Malaya of the National Academy of Sciences of Ukraine”, Ukraine
  • I. F. Grintsov National University of Pharmacy, Ukraine
  • I. A. Otrishko National University of Pharmacy, Ukraine



ischemic heart disease, antiplatelet therapy, acetylsalicilic acid, gender differences


The number of data about the gender differences in cardiovascular diseases course and treatment is continuously growing. The importance of this parameter for the treatment definition is undoubtedly. In this publication the results of comparative activity of plateles gomeostasis in men and women (106 patients) by long-term therapy with acetylsalicilic acid are shown. According to our results, the long-term administration of ASA in standard dosage was inhibiting agregative activity of platelets less effective in women than men. This effect was also most prominent in the case of arachidonat-induced platelets agregation correlating with respond on ASA. The defined in this work gender differences in respond on ASA monotherapy by IHD can be used for further development of treatment guidelines with focus on gender adjusted therapy. Further investigations in this field are crucial.


Барна О.Н. Гендерные аспекты лечения ишемической болезни сердца // Новости медицины и фармации. – 2009. – № 274.

Волков В.И, Запровальная О.Е. Антитромбоцитарная терапия ишемической болезни сердца: проблемы и перспективы // Новости медицины и фармации. – 2011. – №368. – С. 53-59.

Волков В.И., Строна В.И., Запровальная О.Е. Ацетилсалициловая кислота в профилактике атеротромбоза // Здоров’я України. – 2015. – № 3. – С.14-15.

Мітченко О.І. Менопауза та фактори серцево-судинного ризику // Здоров’я України. – 2015. – Кардіологія (тем.номер). – С. 20-21.

Ткачева О.Н. Гендерные особенности антитромбоцитарной тера-пии // Здоров'я України. – 2011. – С. 13.

Юренева С.В., Ильина Л.М., Мычка В.Б. Половые гормоны и сер-дечно-сосудистый риск: критические периоды в жизни женщин // Эффектив-ная фармакотерапия. – 2011. – № 13. – С. 32-37.

Adelman E.E., Lisabeth L., Brown D.l. Gender Differences in the Pri-mary Prevention of Stroke With Aspirin // Medscape Cardiology. – 2011. –

Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of indi-vidual participant data from randomised trials. // Lancet. – 2009. – Vol. 373. – Р.1849-1860.

Becker D.M., Segal J., Vaidya D. et al.: Sex differences in platelet reac-tivity and response to low-dose aspirin therapy. // JAMA. – 2006. – N 295. – P.1420-1427.

Bittner V. Menopause, age, and cardiovascular risk: a complex rela-tionship // J. Am. Coll. Cardiol. – 2009. – Vol. 54, №25. – P. 2374–2375.

Black H.R., Gulati M. Heart Disease: What's Bad for the Goose Is Bad for the Gander // Medscape Cardiology. – 2015. –

Cotreau M.M., von Moltke L.L., Greenblatt D.J. The influence of age and sex on the clearance of cytochrome P450 ЗА substrates // Clin. Pharmacokinet. – 2005. – Vol. 44. – P. 33-60.

Eikelboom J.W., Hirsh J., Weitz J.I. et al. Aspirin-Resistant Thrombox-ane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events // Circulation. – 2002. – Vol.105. – P. 1650-1655.

Meibohm B., Beierle I., Derendorf H. How important are gender differ-ences in pharmacokinetics // Clin. Pharmacokinet. – 2002. – Vol. 41. – P. 329-342.

Nichols M., Townsend N. et al. European Cardiovascular Disease Sta-tistics, 2012 edition. // ESC/Initiatives/EuroHeart/2012-European-Cardiovascular-Disease-Statistics






Clinical Pharmacology and Pharmacotherapy